Related Experiment Video
Updated: Jun 23, 2026
05:44
Rodent Inferior Vena Cava Venoplasty Balloon Model
Published on: May 24, 2024
Pharmacotherapy of vasculitis
1University of Oxford, Nuffield Orthopaedic Centre, Botnar Research Centre, Biomedical Research Unit, Windmill Road, Oxford, OX3 7LD, UK.
Expert Opinion on Pharmacotherapy
|May 19, 2009
Summary
Systemic vasculitis treatment relies on glucocorticoids and immunosuppressants like methotrexate and cyclophosphamide. Careful drug use minimizes toxicity and long-term risks, improving patient survival.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Systemic vasculitides involve blood vessel inflammation, often treated empirically due to unclear causes.
- Current treatments aim to improve survival, especially in severe forms of vasculitis.
Purpose of the Study:
- To systematically review the evidence for drug therapies in treating systemic vasculitides.
- To outline current therapeutic strategies based on disease type and severity.
Main Methods:
- Systematic literature review of drug therapies for vasculitis.
- Analysis of treatment efficacy and toxicity based on disease classification.
Main Results:
- Glucocorticoids are essential, particularly for giant-cell arteritis.
- Immunosuppressants like methotrexate and cyclophosphamide are crucial for specific vasculitis types (e.g., Wegener's granulomatosis, Takayasu's arteritis).
- Biologic therapies are used for resistant cases, with ongoing efforts to reduce cyclophosphamide toxicity.
Conclusions:
- Effective management of systemic vasculitides involves a combination of glucocorticoids and immunosuppressive agents.
- Optimizing drug selection and duration is key to balancing treatment efficacy with patient safety and minimizing long-term adverse effects.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...